Mitra et al. did a nice experiment in which they antagonized the CAF phenotype of the three micro RNAs mentioned. In CAFs, reversal of miR-31 and miR-214 downregulation and reversal of miR-155 upregulation caused reversion of CAFs to a normal phenotype. Designing a treatment based off of these results seems like a logical plan. We will use liposomal delivery to insert complementary miR-31 and miR-214 as well as a complementary strand to miR-155. Fibroblast activated protein (FAP) and a-smooth muscle actin (aSMA) are two cell surface antigens of epithelial ovarian cancer CAFs (Mhawech-Fauceglia et. al). We will engineer a liposome with monoclonal antibodies that can bind to these two cell surface antigens in order to target the CAFs.
Recent comments